Mast Therapeutics Inc (NASDAQ:MSTX) was upgraded by Zacks Investment Research from a “sell” rating to a “buy” rating in a note issued to investors on Friday. The brokerage currently has a $0.25 price objective on the stock. Zacks Investment Research’s target price suggests a potential upside of 103.25% from the stock’s current price.
According to Zacks, “Mast Therapeutics Inc. is a biopharmaceutical research and development company focused on introducing new technologies for anticancer and antiviral treatments. The company’s lead product candidate is MST-188 for treating serious or life-threatening diseases. Mast Therapeutics, Inc., formerly known as ADVENTRX Pharmaceuticals, Inc., is based in San Diego, California. “
Several other analysts also recently weighed in on the company. Maxim Group set a $5.00 price target on Mast Therapeutics and gave the company a “buy” rating in a research note on Wednesday, July 27th. Cowen and Company restated an “outperform” rating on shares of Mast Therapeutics in a research note on Friday. Roth Capital restated a “buy” rating and issued a $2.00 target price on shares of Mast Therapeutics in a research note on Monday, August 1st. Canaccord Genuity restated a “buy” rating and issued a $3.00 target price on shares of Mast Therapeutics in a research note on Thursday, July 28th. Finally, Laidlaw downgraded Mast Therapeutics from a “buy” rating to a “neutral” rating in a research note on Wednesday, September 21st. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Mast Therapeutics has an average rating of “Buy” and an average target price of $2.56.
Mast Therapeutics (NASDAQ:MSTX) opened at 0.123 on Friday. The firm has a 50-day moving average price of $0.43 and a 200-day moving average price of $0.37. Mast Therapeutics has a 12-month low of $0.10 and a 12-month high of $0.71. The company’s market cap is $26.05 million.
Mast Therapeutics (NASDAQ:MSTX) last posted its quarterly earnings results on Tuesday, August 9th. The company reported ($0.05) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.06) by $0.01. On average, analysts forecast that Mast Therapeutics will post ($0.21) earnings per share for the current fiscal year.
An institutional investor recently raised its position in Mast Therapeutics stock. Vanguard Group Inc. raised its position in Mast Therapeutics Inc (NASDAQ:MSTX) by 18.2% during the second quarter, according to its most recent disclosure with the SEC. The firm owned 5,996,047 shares of the company’s stock after buying an additional 923,507 shares during the period. Vanguard Group Inc. owned approximately 3.11% of Mast Therapeutics worth $2,818,000 at the end of the most recent quarter.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mast Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mast Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.